{{chembox
| verifiedrevid = 
| ImageFile=Fidarestat structure.svg
| ImageSize=222
| IUPACName=(2''S'',4''S'')-6-fluoro-2',5'-dioxospiro[2,3-dihydrochromene-4,4'-imidazolidine]-2-carboxamide
| OtherNames=(2''S'',4''S'')-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide

| Section1 = {{Chembox Identifiers 
  | CASNo=136087-85-9; 105300-43-4 (unspecified)
|  PubChem = 160024
|  ChemSpiderID = 140679
  | ChEMBL = 84446
  | UNII_Ref = {{fdacite|correct|FDA}}
  | UNII = 8SH8T1164U
|  SMILES = c1cc2c(cc1F)[C@@]3(C[C@H](O2)C(=O)N)C(=O)NC(=O)N3
|  StdInChI = 1S/C12H10FN3O4/c13-5-1-2-7-6(3-5)12(4-8(20-7)9(14)17)10(18)15-11(19)16-12/h1-3,8H,4H2,(H2,14,17)(H2,15,16,18,19)/t8-,12-/m0/s1
|  StdInChIKey = WAAPEIZFCHNLKK-UFBFGSQYSA-N
|  KEGG = D01842
  }}
| Section2 = {{Chembox Properties
  | C=12 | H=10 | F=1 | N=3 | O=4 
  | MolarMass = 279.22 g/mol
  | Appearance =
  | Density =
  | MeltingPt = 290–300°
  | BoilingPt =
  | Solubility =
  }}
|Section3 = {{Chembox Hazards
  | MainHazards =
  | FlashPt =
  | AutoignitionPt =
  }}
}}

'''Fidarestat''' (SNK-860) is an [[aldose reductase inhibitor]] under investigation for treatment of [[diabetic neuropathy]].

==References==
Aldose reductase inhibitor for treatment of diabetic complications. Prepn (stereo unspec): M. Kurono, et al., EP 193415; eidem, US 4740517 (1986, 1988 both to Sanwa). Prepn of isomers: T. Yamaguchi et al., Arzneim.-Forsch. 44, 344 (1994). Pharmacological profile: K. Mizuno et al. in Current Concepts of Aldose Reductase and Its Inhibitions, N. Sakamoto et al., Eds. (Elsevier, Amsterdam, 1990) pp 89-96. Configuration and crystal structure of complex with aldose reductase: M. Oka et al., J. Med. Chem. 43, 2479 (2000). Clinical efficacy in diabetic peripheral neuropathy: N. Hotta et al., Diabetes Care 24, 1776 (2001). Clinical suppression of sorbitol accumulation in erythrocytes of diabetic patients: T. Asano et al., J. Diabetes Complications 16, 133 (2002); eidem, ibid. 18, 336 (2004). Review of clinical development: N. Giannoukakis, Curr. Opin. Invest. Drugs 4, 1233-1239 (2003).
{{reflist}}

{{oral hypoglycemics}}

[[Category:Aldose reductase inhibitors]]
[[Category:Hydantoins]]
[[Category:Orphan drugs]]

{{gastrointestinal-drug-stub}}